Abstract
CA125 is a tumour marker test based on a monoclonal antibody against an antigen from an ovarian carcinoma cell line. Serum concentrations of CA125 were determined in 95 patients with pancreatic cancer and in 106 patients with benign pancreatic, biliary and hepatocellular diseases. The CA125 concentrations were compared with the CA19-9 and CEA levels. Almost half (45%) of the patients with pancreatic cancer had an elevated CA125 level (greater than 35 U ml-1). Elevated values were also found in benign diseases (24%), especially in patients with pancreatitis and benign hepatocellular diseases, but more seldom in extrahepatic cholestasis. It seems that CA125 is of limited value in the diagnosis of pancreatic cancer. Combination of the CA125 with the CA19-9 test increases the sensitivity only 6% as compared to the CA19-9 assay alone. There may, however, be a use for CA125 in differentiating between obstructive jaundice of benign and malignant origin.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Haglund, C. Tumour marker antigen CA125 in pancreatic cancer: A comparison with CA19-9 and CEA. Br J Cancer 54, 897–901 (1986). https://doi.org/10.1038/bjc.1986.259
Issue Date:
DOI: https://doi.org/10.1038/bjc.1986.259
This article is cited by
-
Postbiotic butyrate: role and its effects for being a potential drug and biomarker to pancreatic cancer
Archives of Microbiology (2024)
-
Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study
BMC Cancer (2022)
-
Health risk assessment based on metal analysis of soil and crops in Al-Dakhla Oasis
Arabian Journal of Geosciences (2021)
-
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
Cancer Chemotherapy and Pharmacology (2019)
-
Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer
World Journal of Surgical Oncology (2014)